Displaying 114 (all) recruiting clinical trials.
-
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Site for Low-grade gliomas (LGG) are the most common central nervous system tumor among children, accounting for approximately one-third of pediatric brain tumors. These tumors ... -
Site for ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Site for This trial studies how well selumetinib works in treating patients with low-grade glioma. Selumetinib is a drug that works by blocking a protein ... -
NAUTIKA1: A Multicenter Phase II Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients with Resectable Stages IB-III Non-Small Cell Lung Cancer
Study ML41591, is an umbrella trial that will evaluate the efficacy and safety of targeted therapies in patients with resectable Stage IA2, IB, II, IIIA ... -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of livmoniplimab (ABBV-151) as a Single Agent and in Combination with budigalimab (ABBV-181) in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
This is a Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of livmoniplimab (ABBV-151) as a ... -
A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
This is a Phase 3, randomized, placebo-controlled, parallel-group, multi-site, double-blind (with in-house blinding) study of pembrolizumab + CRT versus placebo + CRT in participants with MIBC (T2-T4aN0M0 ... -
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Low-grade gliomas (LGG) are the most common central nervous system (CNS) tumors in the pediatric population. Although the etiology of most childhood LGG is unknown ... -
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical ... -
Site for Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
This study will therefore address the question whether docetaxel alone is as active as docetaxel and cetuximab combination and whether either taxane-based regimen is better ...